peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical to present IdeS at the 2014 BIO International Convention in San Diego, USA, on June 26

11 Jun 2014, 14:45
Regulatory information
Hansa Medical will present the drug candidate IdeS, currently in clinical development, as a method for desensitization prior to kidney transplantation, at 10:15 a.m. in the convention’s venue Mission Beach.  

The 2014 BIO International Convention (Biotechnology Industry Organization), June 23 through 26, will be held at the San Diego Convention Center in San Diego, California. The convention gathers international and US-based industry leading parties, prominent keynote speakers, and attracts extensive media coverage.

For more information about the event, please visit:

The CEO presentation will emphasize IdeS’ promising deactivating effect on IgG-antibodies, recently established in a clinical Phase I study and IdeS’ potential as a novel treatment in enabling transplantation in sensitized patients.

More on IdeS
The enzyme IdeS is developed as a fast, safe and expedient method to deactivate anti-HLA antibodies in sensitized patients prior to kidney transplantation. For sensitized patients, anti-HLA antibodies pose the primary obstacle to become transplanted, and the patients are referred to long-term dialysis. A successful Phase I-study with IdeS was finalized in January 2014. A Phase II study application for treatment of sensitized kidney transplantation patients has been approved by the Swedish Medical Products Agency, and the study is scheduled for 2014.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.